 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| NMS-088 / Nerviano Medical Sciences
Enrollment change, Trial completion date, Trial primary completion date: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (clinicaltrials.gov) - Feb 21, 2024
P1/2, N=200, Recruiting, Sponsor: Nerviano Medical Sciences
N=140 --> 200 | Trial completion date: Sep 2023 --> Feb 2026 | Trial primary completion date: Sep 2023 --> Dec 2025
- || NMS-088 / Nerviano Medical Sciences
FLT3、KIT、CSF1を阻害する #NMS088 が、FLT3阻害薬の投与歴がある #FLT3変異 陽性の再発・難治性 #急性骨髄性白血病（#AML）に有用である可能性が明らかとなりました。 #AACR23 https://t.co/OVLDIm1tgO (Twitter) - Apr 17, 2023
- NMS-088 / Nerviano Medical Sciences
NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience (Valencia A - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_3109;
Together with the manageable safety observed, these results warrant further development of this drug including potential as a novel valuable therapeutic option for pts who have exhausted available treatments. The trial is currently opened for enrollment (NTC03922100).
- NMS-P088 / Nerviano Medical Sciences
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5582;
Exploratory endpoints are included to evaluate the potential effects of treatment with NMS-03592088 on circulating levels of CSF1 in plasma, the potential correlation of cellular CSF1R expression levels with clinical outcome in both AML and CMML, and the mutational status of a panel of leukemia-related genes, not limited to FLT3. The Phase I part started in Italy in March, 2019 and is currently ongoing.
- |||| NMS-088 / Nerviano Medical Sciences
New P1/2 trial: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (clinicaltrials.gov) - Apr 18, 2019
P1/2, N=140, Recruiting, Sponsor: Nerviano Medical Sciences